What: 11th North West Lipid & Atherosclerosis Forum
When: Tuesday, 18th September 2018
Where: Radisson BLU Hotel, Chicago Avenue, Manchester Airport, Manchester, M90 3RA
Programme
| 0830 – 0900 | Registration & Coffee | |
| 0900 | Welcome | Dr Handrean Soran |
| 0905 | First Session | Chairs: Dr Michael France & TBC |
| 0910–0940 | Managing hypertension: clinical guidelines and how to individualise treatment? | Professor Anthony Heagerty, University of Manchester, UK |
| 0940-1010 | A systematic evaluation of glucose lowering therapy and cardiovascular risk: past and present. | TBC |
| 1010-1040 | Optimizing treatment of Hyperlipidaemia: quantitative evaluation of UK, USA and European guidelines | Professor Paul Durrington, University of Manchester, UK |
| 1040-1105 | Case presentation
Moderated Panel discussion |
Dr Handrean Soran |
| 1105 – 1135 | Coffee and Networking | |
| 1135 | Second session | Chairs: Professor Sean Carroll and Dr Basil Iissa |
| 1135-1205 | FCS: the disease burden, diagnosis and data from gene therapy. | Prof Elisabeth Steinhagen-Thiessen, Berlin, Germany |
| 1205-1335 | Recent advances in lipid modification therapy: PCSK9i trials and new therapies for severe hypertriglyceridaemia | Dr Handrean Soran, Manchester University Hospital, Manchester, UK |
| 1235-1305 | PCSK9, LDL-R and diabetes: from molecular mechanisms to clinical implications. | Professor Giuseppe Danilo Norata, Milan, Italy |
| 1305-1315 | Panel discussion | |
| 1315 – 1400 | Lunch and Networking | |
| 1400 | Third session | Chairs: Dr Rachelle Donn and Dr Lance Sandle |
| 1400-1430 | HDL cholesterol as a therapeutic target: A critical appraisal of previous clinical trials and how can we do better? | TBC |
| 1430-1500 | Autoimmunity against HDL/apoA-1: an emergent marker and mediator of cardiovascular risk. | Prof Nicolas Vuilleumier, Geneva Faculty of Medicine, Switzerland |
| 1500 – 1515 | Coffee and Networking | |
| 1400 | Fourth session | Chairs: Dr Dermot Neely, Newcastle, UK & TBC |
| 1510-1540 | Lipid lowering nutraceuticals in clinical practice and recent advances | Prof Maceij Banach, Warsaw, Poland |
| 1540-1610 | Lipoprotein (a) as a cardiovascular risk factor: what HEART UK says? | Dr Jaimini Cegla
Imperial College, London |
| 1420–1440 | Coffee and Networking
Feedback/Close |
|
| 1550 | END |
Endodiabesity 